- Halo Pharma will operate as a stand-alone business following the sale of Noramco’s API and related businesses to Siegfried.
- The company is expanding its drug product CDMO and contract manufacturing services, with sterile fill-finish operations planned to come online in the second half of 2026.
Halo Pharma will become a stand-alone business following the sale of the Noramco Group’s API and associated businesses to Siegfried. The transaction results in Halo operating independently as a dedicated platform for drug product pharmaceutical development and manufacturing services.
Halo was acquired by the Noramco Group from Cambrex in 2023. With the divestment of Noramco’s API-related assets, Halo will focus exclusively on drug product CDMO and contract manufacturing activities, spanning sterile and non-sterile dosage forms.
The company’s sterile CDMO operations are expected to come online in the second half of 2026. The planned capabilities include a Groninger UFVN FlexFill filling line with a Skan isolator, designed to support ready-to-use vials, syringes, and cartridges across multiple fill volumes. Halo said it will continue to offer oral solids, liquids, and semi-solids from its two existing sites.
To support the sterile manufacturing investment, Halo has recently launched sterile product development capabilities, including analytical testing and formulation services. The expansion is intended to support demand from pharmaceutical customers seeking sterile drug product manufacturing.
“Anytime you can focus on doing one thing really well, success is inevitable. The company is seeing interest from established pharmaceutical companies looking to secure sterile CDMO services in advance of the planned launch.”
Lee Karras, CEO of the Noramco Group
